Embecta Corp Net Assets
Embecta Corp net assets. Based on the latest financial reports, Embecta Corp (EMBC) has net assets worth $-612.70 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.27 Billion) and total liabilities ($1.88 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore EMBC net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-612.70 Million |
| % of Total Assets | -48.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -209.63% |
| 10-Year Change | N/A |
| Growth Volatility | 117.09 |
Net Assets of Embecta Corp (2019–2025)
Net assets of Embecta Corp from 2019 to 2025. This chart illustrates how Embecta Corp's net assets have evolved over time, based on quarterly financial data. See Embecta Corp (EMBC) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Embecta Corp (2019–2025)
The table below shows the annual net assets of Embecta Corp from 2019 to 2025. For live market cap and overall valuation, see market cap of Embecta Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $-651.20 Million | +11.80% |
| 2024-09-30 | $-738.30 Million | +10.15% |
| 2023-09-30 | $-821.70 Million | +7.82% |
| 2022-09-30 | $-891.40 Million | -250.07% |
| 2021-09-30 | $594.00 Million | +3.85% |
| 2020-09-30 | $572.00 Million | -7.59% |
| 2019-09-30 | $619.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Embecta Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44560000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Embecta Corp Net Assets Breakdown (September 2025)
Embecta Corp net assets breakdown by equity component as of September 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $600.00K | % |
| Other Comprehensive Income | $-285.60 Million | % |
| Other Components | $79.40 Million | % |
| Total Equity | $-651.20 Million | 100.00% |
Embecta Corp Competitors by Market Cap
The table below lists competitors of Embecta Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Invesco Municipal Income Opportunities Closed Fund Class Common
NYSE:OIA
|
$279.92 Million |
|
XiAn Typical Industries Co Ltd
SHG:600302
|
$280.00 Million |
|
NACL Industries Limited
NSE:NACLIND
|
$280.00 Million |
|
Marine Products Corporation
NYSE:MPX
|
$280.04 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
$279.88 Million |
|
Long Yuan Construction Group Co Ltd
SHG:600491
|
$279.81 Million |
|
Arvind SmartSpaces Limited
NSE:ARVSMART
|
$279.69 Million |
|
ADF Foods Limited
NSE:ADFFOODS
|
$279.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Embecta Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -738,300,000 to -651,200,000, a change of 87,100,000.
- Net income of 95,400,000 contributed positively to equity growth.
- Dividend payments of 35,000,000 reduced retained earnings.
- Share repurchases of 5,700,000 reduced equity.
- Other comprehensive income increased equity by 7,200,000.
- Other factors increased equity by 25,200,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $95.40 Million | +14.65% |
| Dividends Paid | $35.00 Million | -5.37% |
| Share Repurchases | $5.70 Million | -0.88% |
| Other Comprehensive Income | $7.20 Million | +1.11% |
| Other Changes | $25.20 Million | +3.87% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Embecta Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | $10.12 | $6.25 | x |
| 2020-09-30 | $10.04 | $6.25 | x |
| 2021-09-30 | $10.46 | $6.25 | x |
| 2022-09-30 | $-15.62 | $6.25 | x |
| 2023-09-30 | $-14.23 | $6.25 | x |
| 2024-09-30 | $-12.66 | $6.25 | x |
| 2025-09-30 | $-11.05 | $6.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Embecta Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.83%
- • Asset Turnover: 0.99x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (31.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 74.87% | 38.95% | 1.49x | 1.29x | $374.30 Million |
| 2020 | 74.76% | 39.39% | 1.47x | 1.29x | $370.40 Million |
| 2021 | 69.83% | 35.61% | 1.48x | 1.33x | $355.40 Million |
| 2022 | 0.00% | 19.80% | 1.04x | 0.00x | $312.74 Million |
| 2023 | 0.00% | 6.28% | 0.92x | 0.00x | $152.57 Million |
| 2024 | 0.00% | 6.97% | 0.87x | 0.00x | $152.13 Million |
| 2025 | 0.00% | 8.83% | 0.99x | 0.00x | $160.52 Million |
Industry Comparison
This section compares Embecta Corp's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,520,089,226
- Average return on equity (ROE) among peers: -106.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Embecta Corp (EMBC) | $-612.70 Million | 74.87% | N/A | $279.90 Million |
| Akoya Biosciences Inc (AKYA) | $7.59 Million | -728.97% | 15.46x | $64.44 Million |
| Align Technology Inc (ALGN) | $83.56 Million | -41.84% | 0.81x | $10.73 Billion |
| AngioDynamics Inc (ANGO) | $37.23 Million | 8.44% | 0.34x | $495.58 Million |
| AptarGroup Inc (ATR) | $1.17 Billion | 17.51% | 1.22x | $7.66 Billion |
| AtriCure Inc (ATRC) | $30.69 Million | -44.69% | 0.27x | $2.21 Billion |
| Avinger Inc (AVGR) | $6.89 Million | -286.47% | 2.46x | $1.52 Million |
| Avantor Inc (AVTR) | $2.67 Billion | 4.36% | 2.70x | $9.19 Billion |
| Azenta Inc (AZTA) | $542.40 Million | -43.63% | 0.22x | $1.35 Billion |
| Baxter International Inc (BAX) | $8.16 Billion | 30.62% | 2.20x | $11.89 Billion |
| Becton Dickinson and Company (BDX) | $2.49 Billion | 19.29% | 1.03x | $48.93 Billion |
About Embecta Corp
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors… Read more